NEW YORK (GenomeWeb) – Somalogic said today that Novartis has extended its multi-year research agreement covering the use of Somalogic's aptamer-based proteomics platform for drug development work.

Under the extended agreement, the two companies will continue efforts begun under an initial 2011 agreement to build a proprietary version of Somalogic's SomaScan proteomics assay and develop novel Somamer binding reagents for preclinical and clinical applications in Novartis's portfolio.

Novartis will also take an equity stake in Somalogic as part of the agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.